FULGENT GENETICS, INC. Form 8-K (May 20, 2021)

Summary

FULGENT GENETICS, INC. Form 8-K with a May 20, 2021 date of earliest event reported, filed under Item 5.07, Submission of Matters to a Vote of Security Holders. At the annual meeting of stockholders, which took place on May 20, 2021, a quorum of 20,169,388 shares, approximately 70% of the 28,989,270 eligible shares, was present in person or by proxy. Stockholders elected Ming Hsieh, John Bolger, Yun Yen and Linda Marsh as directors, with votes for ranging from 12,798,371 to 13,111,071. They also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2021, with 20,059,361 votes for, 73,241 against and 36,786 abstained.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" flgt-8k_20210520.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2021

FULGENT GENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware | 001-37894 | 81-2621304
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
4978 Santa Anita Avenue Temple City, California | 91780
(Address of Principal Executive Offices) | (Zip Code)

(626) 350-0537

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, par value $0.0001 per share | FLGT | The Nasdaq Stock Market (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Fulgent Genetics, Inc. (the “Company”) was held on May 20, 2021 at 9:00 a.m. Pacific Daylight Time at the Company’s offices at 4401 Santa Anita Avenue, Suite 214, El Monte, California 91731. Of the Company’s 28,989,270 shares of common stock issued and outstanding and eligible to vote as of the record date of March 26, 2021, a quorum of 20,169,388 shares, or approximately 70% of the eligible shares, was present in person or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 1, 2021. The following actions were taken at the Annual Meeting:

Proposal 1

Election of the following nominees as directors of the Company, each to serve until the 2022 Annual Meeting and until his or her successor is duly elected and qualified.

Votes For | Votes Withheld | Broker Non-Vote
Ming Hsieh | 13,111,071 | 140,707 | 6,917,610
John Bolger | 13,091,491 | 160,287 | 6,917,610
Yun Yen, M.D., Ph.D., F.A.C.P. | 12,798,371 | 453,407 | 6,917,610
Linda Marsh | 13,090,514 | 161,264 | 6,917,610

Proposal 2

Ratification of the selection of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the year ending December 31, 2021.

Votes For | Votes Against | Votes Abstained | Broker Non-Vote
20,059,361 | 73,241 | 36,786 | —

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FULGENT GENETICS, INC.
Date: May 20, 2021 | By: | /s/ Paul Kim
Paul Kim Chief Financial Officer

File and source

File

SEC_FLGT_8-K_filed2021-05-20_0001564590-21-029110.htm

Size

58,672 bytes

SHA-256

81af5d06a3aaac6362840e1bec6768377158b2e8d9ff8ad1bd7579deef736b1c

Our copy

SEC_FLGT_8-K_filed2021-05-20_0001564590-21-029110.htm

Original

www.sec.gov